TIDMMPH
Mereo BioPharma Group plc
16 November 2020
Mereo BioPharma to Hold Virtual R&D Day on Tuesday, November
24, 2020
London and Redwood City, Calif., November 16, 2020 - Mereo
BioPharma Group plc (NASDAQ: MREO, AIM: MPH) ("Mereo" or "the
Company"), a clinical stage biopharmaceutical company focused on
oncology and rare diseases, today announced it will host a virtual
R&D day on Tuesday, November 24, to review the Company's key
pipeline programs including etigilimab (Anti-TIGIT) for solid
tumors and alvelestat for alpha-1 antitrypsin deficiency (AATD) and
COVID-19 respiratory disease. The virtual R&D day will feature
external experts and will include a more detailed review of the
etigilimab development program, including the design and biomarker
strategy for the recently initiated Phase 1b/2 basket combination
study.
R&D Day Information
Date: Tuesday, November 24, 2020
Time: 12:00 p.m. EST / 5:00 p.m. GMT
Presenters:
-- Timothy Yap, MBBS, PhD, FRCP, Associate Professor, Department
of Investigational Cancer Therapeutics, and the Department of
Thoracic/Head and Neck Medical Oncology, The University of Texas MD
Anderson Cancer Center
-- John Strickler, MD, Associate Professor of Medicine, Member of the Duke Cancer Institute
-- Mark Dransfield, MD, Professor and Interim Director, Division
of Pulmonary, Allergy and Critical Care Medicine, The University of
Alabama at Birmingham (UAB)
-- Denise Scots-Knight, Chief Executive Officer
-- John Lewicki, Chief Scientific Officer
-- Ann Kapoun, SVP of Translational Research and Development
-- Alastair MacKinnon, Chief Medical Officer
-- Jackie Parkin, Head of the Alvelestat Program
A live audio webcast of the R&D day can be accessed through
the Investors section of the company's website at
www.mereobiopharma.com/investors/results-reports-and-presentations
. The event is expected to last approximately two hours. An
archived replay of the webcast will be made available on the
Company's website.
About Mereo BioPharma
Mereo BioPharma is a biopharmaceutical company focused on the
development and commercialization of innovative therapeutics that
aim to improve outcomes for oncology and rare diseases. Mereo's
lead oncology product candidate, etigilimab (Anti-TIGIT), has
completed a Phase 1a dose escalation clinical trial in patients
with advanced solid tumors and has been evaluated in a Phase 1b
study in combination with nivolumab in select tumor types. The
Company recently announced initiation of a Phase 1b/2 study of
etigilimab in combination with an anti-PD-1/PDL-1 in a range of
different tumor types. Mereo's rare disease product portfolio
consists of setrusumab, which has completed a Phase 2b dose-ranging
study in adults with osteogenesis imperfecta (OI), as well as
alvelestat, which is being investigated in a Phase 2
proof-of-concept clinical trial in patients with alpha-1
antitrypsin deficiency (AATD) and in a Phase 1b/2 clinical trial in
COVID-19 respiratory disease.
Forward-Looking Statements
This Announcement contains "forward-looking statements." All
statements other than statements of historical fact contained in
this Announcement are forward-looking statements within the meaning
of Section 27A of the United States Securities Act of 1933, as
amended and Section 21E of the United States Securities Exchange
Act of 1934, as amended. Forward-looking statements usually relate
to future events and anticipated revenues, earnings, cash flows or
other aspects of our operations or operating results.
Forward-looking statements are often identified by the words
"believe," "expect," "anticipate," "plan," "intend," "foresee,"
"should," "would," "could," "may," "estimate," "outlook" and
similar expressions, including the negative thereof. The absence of
these words, however, does not mean that the statements are not
forward-looking. These forward-looking statements are based on the
Company's current expectations, beliefs and assumptions concerning
future developments and business conditions and their potential
effect on the Company. While management believes that these
forward-looking statements are reasonable as and when made, there
can be no assurance that future developments affecting the Company
will be those that it anticipates.
All of the Company's forward-looking statements involve known
and unknown risks and uncertainties some of which are significant
or beyond its control and involve assumptions that could cause
actual results to differ materially from the Company's historical
experience and its present expectations or projections.
These forward-looking statements are subject to risks and
uncertainties, including, among other things, those described in
the Company's latest Annual Report on Form 20-F, Reports on Form
6-K and other documents filed from time to time by the Company with
the United States Securities and Exchange Commission. The Company
wishes to caution investors not to place undue reliance on any
forward-looking statements, which speak only as of the date hereof.
The Company undertakes no obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise, except to the extent
required by law.
Mereo BioPharma Contacts:
Mereo +44 (0)333 023 7300
Denise Scots-Knight, Chief Executive Officer
N+1 Singer (Nominated Adviser and Broker to Mereo ) +44 (0)20 7496 3081
Phil Davies
Will Goode
Burns McClellan (US Investor Relations Adviser to Mereo ) + 01 212 213 0006
Lisa Burns
Lee Roth
FTI Consulting (UK Public Relations Adviser to Mereo ) +44 (0)20 3727 1000
Simon Conway
Ciara Martin
Investors investors@ mereo biopharma.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAXELLFBFLXFBQ
(END) Dow Jones Newswires
November 16, 2020 07:00 ET (12:00 GMT)
Mereo Biopharma (LSE:MPH)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
Mereo Biopharma (LSE:MPH)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025
